{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:20:40Z","timestamp":1782843640912,"version":"3.54.5"},"reference-count":115,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH","award":["NIH K23-DK114460"],"award-info":[{"award-number":["NIH K23-DK114460"]}]},{"name":"NIH","award":["C-Sig P30DK84567"],"award-info":[{"award-number":["C-Sig P30DK84567"]}]},{"name":"ANMS Career Development Award"},{"name":"Mayo Clinic Center for Individualized Medicine\u2014Gerstner Career Development Award and Magnus Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the recent urbanization and globalization, the adult obesity rate has been increasing, which was paralleled with a dramatic surge in the incidence and prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD poses a growing threat to human health as it represents the most common cause of chronic liver disease in developed countries. It encompasses a wide spectrum of conditions starting from a build-up of fat in hepatocytes (steatosis), to developing inflammation (steatohepatitis), and reaching up to cirrhosis. It is also associated with higher rates of cardiovascular mortalities. Therefore, proper timely treatment is essential and weight loss remains the cornerstone in the treatment of obesity-related liver diseases. When diet, exercise, and lifestyle changes are not successful, the current recommendation for weight loss includes antiobesity medications and bariatric endoscopic and surgical interventions. These interventions have shown to result in significant weight loss and improve liver steatosis and fibrosis. In the current literature review, we highlight the expected outcomes and side effects of the currently existing options to have a weight-centric NAFLD approach.<\/jats:p>","DOI":"10.1055\/s-0041-1731704","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T23:50:17Z","timestamp":1625874617000},"page":"435-447","source":"Crossref","is-referenced-by-count":24,"title":["Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review"],"prefix":"10.1055","volume":"41","author":[{"given":"Anas","family":"Hashem","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Precision Medicine for Obesity Program, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Khalouf","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Precision Medicine for Obesity Program, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Precision Medicine for Obesity Program, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ecl.2016.04.004","article-title":"Regarding obesity as a disease: evolving policies and their implications","volume":"45","author":"T K Kyle","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fendo.2019.00065","article-title":"Systemic metabolism, its regulators, and cancer: past mistakes and future potential","volume":"10","author":"J MP Holly","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"K M Flegal","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/oby.2008.351","article-title":"Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic","volume":"16","author":"Y Wang","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1053\/j.gastro.2016.12.052","article-title":"Gastrointestinal complications of obesity","volume":"152","author":"M Camilleri","year":"2017","journal-title":"Gastroenterology"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3748\/wjg.v25.i3.282","article-title":"Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies","volume":"25","author":"W K Seto","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1503\/cmaj.045232","article-title":"Nonalcoholic fatty liver disease","volume":"172","author":"L A Adams","year":"2005","journal-title":"CMAJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"S Mitra","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans","volume":"14","author":"F Kanwal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"R Divella","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"39","key":"ref13","doi-asserted-by":"crossref","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"W Dai","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"E Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"02","key":"ref15","first-page":"147","article-title":"Non-alcoholic fatty liver disease: an update on diagnosis","volume":"91","author":"D L Dumitrascu","year":"2018","journal-title":"Clujul Med"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"E M Brunt","year":"2011","journal-title":"Hepatology"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"P Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"04","key":"ref18","first-page":"242","article-title":"Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"7","author":"S-A Hashemi","year":"2016","journal-title":"Caspian J Intern Med"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ajg.2016.65","article-title":"Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study","volume":"111","author":"R Loomba","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"21","key":"ref20","doi-asserted-by":"crossref","first-page":"e10605","DOI":"10.1097\/MD.0000000000010605","article-title":"Diagnostic performance of magnetic resonance technology in detecting steatosis or fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"97","author":"X M Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"27","key":"ref21","first-page":"9026","article-title":"Role of liver biopsy in nonalcoholic fatty liver disease","volume":"20","author":"I L Nalbantoglu","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"09","key":"ref22","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study","volume":"103","author":"W Dunn","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2020.02.028","article-title":"Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH","volume":"73","author":"J Ampuero","year":"2020","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/HMER.S188991","article-title":"A review of current and upcoming treatment modalities in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"11","author":"S Ganguli","year":"2019","journal-title":"Hepat Med"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cgh.2016.10.023","article-title":"White Paper AGA: POWER\u2014practice guide on obesity and weight management, education, and resources","volume":"15","author":"A Acosta","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cld.2015.10.008","article-title":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease","volume":"20","author":"W N Hannah Jr","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1440-1746.2008.05694.x","article-title":"Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors","volume":"24","author":"A St George","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Y Gepner","year":"2019","journal-title":"J Hepatol"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4254\/wjh.v4.i7.224","article-title":"Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China","volume":"4","author":"W-H Sun","year":"2012","journal-title":"World J Hepatol"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"K Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756283X13484078","article-title":"Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial","volume":"6","author":"C Eckard","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(97)80287-5","article-title":"Therapeutic effects of restricted diet and exercise in obese patients with fatty liver","volume":"27","author":"T Ueno","year":"1997","journal-title":"J Hepatol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/00365520802588133","article-title":"Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol","volume":"44","author":"K Yasutake","year":"2009","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1155\/2008\/810961","article-title":"Soft drink consumption linked with fatty liver in the absence of traditional risk factors","volume":"22","author":"N Assy","year":"2008","journal-title":"Can J Gastroenterol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"G Musso","year":"2012","journal-title":"Diabetologia"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"E Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"09","key":"ref37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa0804748","article-title":"Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates","volume":"360","author":"F M Sacks","year":"2009","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12876-016-0426-3","article-title":"A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol","volume":"16","author":"E S Papamiltiadous","year":"2016","journal-title":"BMC Gastroenterol"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"E800","DOI":"10.3390\/nu9080800","article-title":"Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease","volume":"9","author":"T Eslamparast","year":"2017","journal-title":"Nutrients"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"M C Ryan","year":"2013","journal-title":"J Hepatol"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1249\/MSS.0000000000000664","article-title":"Updating ACSM's recommendations for exercise preparticipation health screening","volume":"47","author":"D Riebe","year":"2015","journal-title":"Med Sci Sports Exerc"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"M D Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"ref43","first-page":"1492","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"S B Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"S B Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2213-8587(15)00009-1","article-title":"Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations","volume":"3","author":"C N Ochner","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/oby.22189","article-title":"Metabolic adaptations to weight loss","volume":"26","author":"K D Hall","year":"2018","journal-title":"Obesity (Silver Spring)"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"879.e1","DOI":"10.1016\/j.amjmed.2016.02.009","article-title":"FDA-approved anti-obesity drugs in the United States","volume":"129","author":"H L Daneschvar","year":"2016","journal-title":"Am J Med"},{"issue":"03","key":"ref48","first-page":"86","article-title":"Exenatide","volume":"40","author":"K A Gryskiewicz","year":"2005","journal-title":"Formulary"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u2009mg of liraglutide in weight management","volume":"373","author":"X Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"07","key":"ref50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14779072.2015.1054810","article-title":"Liraglutide for type 2 diabetes and obesity: a 2015 update","volume":"13","author":"E W Iepsen","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"M J Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"P N Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"S 03","key":"ref53","first-page":"S12","article-title":"Mode of action of orlistat","volume":"21","author":"R Guerciolini","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/ajcn\/80.6.1461","article-title":"Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials","volume":"80","author":"B Hutton","year":"2004","journal-title":"Am J Clin Nutr"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.2006.106021","article-title":"Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis","volume":"56","author":"N Assy","year":"2007","journal-title":"Gut"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"S A Harrison","year":"2009","journal-title":"Hepatology"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2036.2004.02153.x","article-title":"A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients","volume":"20","author":"S A Harrison","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2337\/diacare.27.1.33","article-title":"Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes","volume":"27","author":"D E Kelley","year":"2004","journal-title":"Diabetes Care"},{"issue":"05","key":"ref59","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"S Zelber-Sagi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pcl.2010.10.007","article-title":"Pharmacotherapy for obese adolescents","volume":"58","author":"D E Greydanus","year":"2011","journal-title":"Pediatr Clin North Am"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MJT.0b013e31817fde95","article-title":"Appetite suppressants, cardiac valve disease and combination pharmacotherapy","volume":"16","author":"R B Rothman","year":"2009","journal-title":"Am J Ther"},{"key":"ref62","first-page":"267","article-title":"Phentermine and topiramate for the management of obesity: a review","volume":"7","author":"G Cosentino","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"03","key":"ref63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review","volume":"95","author":"A Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/oby.2004.206","article-title":"Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects","volume":"12","author":"A Astrup","year":"2004","journal-title":"Obes Res"},{"issue":"08","key":"ref65","first-page":"446","article-title":"Phentermine\/Topiramate extended-release capsules (qsymia) for weight loss","volume":"38","author":"D J Lonneman Jr","year":"2013","journal-title":"P&T"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2014.11.020","article-title":"Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy","volume":"148","author":"A Acosta","year":"2015","journal-title":"Gastroenterology"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"D B Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/14737175.7.1.17","article-title":"Bupropion for weight reduction","volume":"7","author":"K M Gadde","year":"2007","journal-title":"Expert Rev Neurother"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"F L Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"issue":"03","key":"ref70","first-page":"370","article-title":"The efficacy and safety of the naltrexone\/bupropion combination for the treatment of obesity: an update","volume":"14","author":"G A Christou","year":"2015","journal-title":"Hormones (Athens)"},{"issue":"03","key":"ref71","first-page":"164","article-title":"Naltrexone\/Bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults","volume":"41","author":"M M Sherman","year":"2016","journal-title":"P&T"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"F L Greenway","year":"2010","journal-title":"Lancet"},{"key":"ref74","first-page":"1268A","article-title":"Naltrexone\/bupropion extended-release 32\u2009mg\/360\u2009mg significantly improves liver enzymes in obese\/overweight individuals with elevated liver enzymes","volume":"62","author":"A H Allison Winokur","year":"2015","journal-title":"Hepatology"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials","volume":"23","author":"H S Bajaj","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2019.07.026","article-title":"Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease","volume":"71","author":"B K Abu Dayyeh","year":"2019","journal-title":"J Hepatol"},{"issue":"07","key":"ref77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11695-010-0131-1","article-title":"Bariatric surgery versus lifestyle interventions for morbid obesity\u2014changes in body weight, risk factors and comorbidities at 1 year","volume":"21","author":"C Martins","year":"2011","journal-title":"Obes Surg"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"T K Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"04","key":"ref79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11938-017-0158-7","article-title":"Endoscopic treatments for obesity","volume":"15","author":"G Pajot","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.soard.2015.12.026","article-title":"American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons","volume":"12","author":"M R Ali","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.gie.2015.01.054","article-title":"Balancing risk and reward: a critical review of the intragastric balloon for weight loss","volume":"81","author":"S Gaur","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"09","key":"ref82","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s11695-018-3227-7","article-title":"Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials","volume":"28","author":"F Bazerbachi","year":"2018","journal-title":"Obes Surg"},{"issue":"24","key":"ref83","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.3748\/wjg.v22.i24.5495","article-title":"Current status of intragastric balloon for obesity treatment","volume":"22","author":"S H Kim","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"01","key":"ref86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"F Bazerbachi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"09","key":"ref87","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s10620-016-4178-2","article-title":"Effect of intragastric balloons on liver enzymes: a systematic review and meta-analysis","volume":"61","author":"V B Popov","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s11695-020-05084-0","article-title":"Efficacy and safety of intragastric balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a Comprehensive review and meta-analysis","volume":"31","author":"S Chandan","year":"2021","journal-title":"Obes Surg"},{"issue":"05","key":"ref89","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.gie.2015.02.023","article-title":"Endoscopic bariatric therapies","volume":"81","author":"B K Abu Dayyeh","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"08","key":"ref90","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s11695-015-1714-7","article-title":"Endoscopic sleeve gastroplasty: how I do it?","volume":"25","author":"G Lopez-Nava","year":"2015","journal-title":"Obes Surg"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cgh.2015.12.030","article-title":"Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals","volume":"15","author":"B K Abu Dayyeh","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2016.12.012","article-title":"Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients","volume":"15","author":"R Z Sharaiha","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.soard.2019.11.012","article-title":"Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis","volume":"16","author":"S Singh","year":"2020","journal-title":"Surg Obes Relat Dis"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.gie.2020.08.023","article-title":"Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty","volume":"93","author":"K Hajifathalian","year":"2021","journal-title":"Gastrointest Endosc"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cgh.2019.08.022","article-title":"Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis","volume":"18","author":"A Hedjoudje","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gutjnl-2019-318349","article-title":"Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study","volume":"69","author":"A CG van Baar","year":"2020","journal-title":"Gut"},{"issue":"03","key":"ref97","doi-asserted-by":"crossref","first-page":"E550","DOI":"10.1152\/ajpendo.00326.2004","article-title":"Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP","volume":"290","author":"M J Theodorakis","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"E379","DOI":"10.1210\/jc.2010-1333","article-title":"Small intestinal alterations in severely obese hyperglycemic subjects","volume":"96","author":"F J Verdam","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"05","key":"ref99","doi-asserted-by":"crossref","first-page":"E685","DOI":"10.1055\/a-0862-0263","article-title":"Histologic assessment of the intestinal wall following duodenal mucosal resurfacing (DMR): a new procedure for the treatment of insulin-resistant metabolic disease","volume":"7","author":"E GH de Moura","year":"2019","journal-title":"Endosc Int Open"},{"issue":"12","key":"ref100","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc16-0383","article-title":"Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study","volume":"39","author":"H Rajagopalan","year":"2016","journal-title":"Diabetes Care"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s11695-020-05170-3","article-title":"Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis","volume":"31","author":"G HP de Oliveira","year":"2021","journal-title":"Obes Surg"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.soard.2019.12.022","article-title":"American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States","volume":"16","author":"W J English","year":"2020","journal-title":"Surg Obes Relat Dis"},{"issue":"14","key":"ref104","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","article-title":"Bariatric surgery: a systematic review and meta-analysis","volume":"292","author":"H Buchwald","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"ref105","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1161\/CIRCRESAHA.116.307591","article-title":"Treatment of obesity: weight loss and bariatric surgery","volume":"118","author":"B M Wolfe","year":"2016","journal-title":"Circ Res"},{"issue":"04","key":"ref106","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"G Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"41","key":"ref107","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.3748\/wjg.v21.i41.11804","article-title":"Laparoscopic sleeve gastrectomy: more than a restrictive bariatric surgery procedure?","volume":"21","author":"D Benaiges","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"12","key":"ref108","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.soard.2019.09.060","article-title":"Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria","volume":"15","author":"D Baldwin","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"02","key":"ref109","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.soard.2016.08.011","article-title":"Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies","volume":"13","author":"S Shoar","year":"2017","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"ref110","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","article-title":"Bariatric surgery and long-term durability of weight loss","volume":"151","author":"M L Maciejewski","year":"2016","journal-title":"JAMA Surg"},{"issue":"01","key":"ref111","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11695-019-04118-6","article-title":"Laparoscopic sleeve gastrectomy on the horizon as a promising treatment modality for NAFLD","volume":"30","author":"M A Salman","year":"2020","journal-title":"Obes Surg"},{"issue":"10","key":"ref112","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/s11695-010-0192-1","article-title":"Is the Roux limb a determinant for meal size after gastric bypass surgery?","volume":"20","author":"P Bj\u00f6rklund","year":"2010","journal-title":"Obes Surg"},{"key":"ref113","first-page":"192","article-title":"Surgery in the patient with liver disease","volume":"121","author":"L S Friedman","year":"2010","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"12","key":"ref114","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s11695-015-1696-5","article-title":"Prevalence of non-alcoholic fatty liver disease and steatohepatitis risk factors in patients undergoing bariatric surgery","volume":"25","author":"S Morita","year":"2015","journal-title":"Obes Surg"},{"issue":"11","key":"ref115","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s11695-015-1655-1","article-title":"Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese south Indian patients undergoing bariatric surgery","volume":"25","author":"P Praveenraj","year":"2015","journal-title":"Obes Surg"},{"issue":"06","key":"ref116","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Y Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"ref117","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1007\/s11695-016-2280-3","article-title":"Monitoring of liver function tests after Roux-en-Y gastric bypass: an examination of evidence base","volume":"26","author":"K K Mahawar","year":"2016","journal-title":"Obes Surg"},{"key":"ref118","first-page":"104","article-title":"Liver failure after bariatric surgery\u2013clinical case and literature review","volume":"1","author":"I Mocanu","year":"2018","journal-title":"J Gastroenterol Metabol"},{"issue":"01","key":"ref119","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"H Wang","year":"2018","journal-title":"Biomed Rep"},{"issue":"01","key":"ref120","first-page":"6","article-title":"Obesity management: clinical review and update of the pharmacologic treatment options","volume":"33","author":"R A Plodkowski","year":"2016","journal-title":"Fed Pract"},{"issue":"03","key":"ref121","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post-hoc analysis from 4 RCTs","volume":"23","author":"S Harpreet","year":"2021","journal-title":"Diabetes Obes Metab"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1731704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T23:14:55Z","timestamp":1633475695000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1731704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":115,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,10,5]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1731704","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}